When Pat Sullivan joined Insulet (NSDQ:PODD) in 2014, the Billerica, Mass.-based company was reeling in roughly $300 million in revenue selling its Omnipod tubless insulin delivery system. Sullivan, a veteran of the medtech industry, saw a path to creating a billion-dollar company and it centered around the concept of making life easier for people with diabetes. […]
Insulet
Insulet slides on Q2 revenue miss
Insulet (NSDQ:PODD) shares took a hit today after the company reported second-quarter revenues that missed the consensus forecast and cut its outlook for the rest of the year. Billerica, Mass.-based Insulet reported losses of -$1.7 million, or -3¢ per share, on sales of $124.3 million for the three months ended June 30, amounting to a -78.2% […]
Insulet settles shareholder suit over Omnipod Eros device
Insulet (NSDQ:PODD) shareholders have agreed to settle a lawsuit alleging that the device-maker misrepresented the success of its Omnipod Eros roll-out in 2013. The financial details of the settlement were undisclosed, but it includes $425,000 in attorney fees and an array of corporate compliance enhancements that Insulet plans to adopt. Shareholders Raqim Walker and Frank Carnazza alleged […]
Insulet extends deal with Glooko in Europe
Insulet (NSDQ:PODD) said today that it inked a deal with Glooko to connect data from Insulet’s Omnipod insulin delivery devices in Europe with the Glooko+diasend diabetes data management system. Glooko touted that its data management tech is used at roughly 7,000 provider sites across 23 countries. The Glooko+diasend system allows users to sync and review data […]
Insulet’s Omnipod nabs preferred insulin pump status in British Columbia
Insulet (NSDQ:PODD) said today that its Omnipod device was selected as the preferred insulin pump in British Columbia, Canada under the province’s expanded PharmaCare insulin pump program. According to the terms of the program, any eligible individual who requests an initial or replacement insulin pump will receive coverage for the Billerica, Mass.-based company’s device. There are […]
Insulet assumes direct commercial operations in Europe
Insulet (NSDQ:PODD) said today that it has assumed direct commercial operations in Europe for its Omnipod tubeless insulin pump. The Billerica, Mass.-based company first announced it would part ways with its former European distributor, Ypsomed, in July last year. Insulet has since established a team of more than 100 employees to take care of distributing and […]
Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech
Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device. The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults […]
Closed-loop insulin delivery systems shine at annual diabetes meeting
As device-makers, healthcare practitioners and people with diabetes convened at this year’s annual meeting of the American Diabetes Association, one major theme emerged: the industry is catching on to the potential of closed-loop insulin delivery systems. Major medical technology companies, including Medtronic and Insulet, touted data at this year’s meeting demonstrating the benefits of their […]
FDA clears Insulet’s Omnipod Dash insulin management system
Insulet (NSDQ:PODD) said today that the FDA granted 510(k) clearance to its Omnipod Dash insulin management system. The system wirelessly connects the company’s Personal Diabetes Manager with its tubeless, waterproof insulin pump. The PDM calculates how much insulin should be administered using blood glucose readings from the Contour Next One blood glucose meter. Altogether, the system […]
Insulet sales grow 22% in Q1
Insulet (NSDQ:PODD) topped estimates on Wall Street yesterday with its first-quarter results, topping analysts’ sales expectations by $1.9 million. The Billerica, Mass.-based company reeled in its losses, posting a net loss of -$6.6 million, or -11¢ per share, on sales of $123.6 million for the 3 months ended March 31, for bottom-line growth of 34.2% on […]
